EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing

Jacob Appelbaum, April E Price, Kaori Oda, Joy Zhang, Wai-Hang Leung, Giacomo Tampella, Dong Xia, Pauline Pl So, Sarah K Hilton, Claudya Evandy, Semanti Sarkar, Unja Martin und 26 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci162593 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Jacob Appelbaum und 37 weiteren Autor:innen. Beteiligte Einrichtung: Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sialic Acid Binding Ig-like Lectin 3, Sirolimus, T-Lymphocytes. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Society of Hematology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) designs that incorporate pharmacologic control are desirable; however, designs suitable for clinical translation are needed. We designed a fully human, rapamycin-regulated drug product for targeting CD33 + tumors called dimerizaing agent–regulated immunoreceptor complex (DARIC33). T cell products demonstrated target-specific and rapamycin-dependent cytokine release, transcriptional responses, cytotoxicity, and in vivo antileukemic activity in the presence of as little as 1 nM rapamycin. Rapamycin withdrawal paused DARIC33-stimulated T cell effector functions, which were restored following reexposure to rapamycin, demonstrating reversible effector function control. While rapamycin-regulated DARIC33 T cells were highly sensitive to target antigen, CD34 + stem cell colony-forming capacity was not impacted. We benchmarked DARIC33 potency relative to CD19 CAR T cells to estimate a T cell dose for clinical testing. In addition, we integrated in vitro and preclinical in vivo drug concentration thresholds for off-on state transitions, as well as murine and human rapamycin pharmacokinetics, to estimate a clinically applicable rapamycin dosing schedule. A phase I DARIC33 trial has been initiated (PLAT-08, NCT05105152), with initial evidence of rapamycin-regulated T cell activation and antitumor impact. Our findings provide evidence that the DARIC platform exhibits sensitive regulation and potency needed for clinical application to other important immunotherapy targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteSialic Acid Binding Ig-like Lectin 3SirolimusT-LymphocytesAnimalsFemaleHumansMaleMiceImmunotherapy, AdoptiveReceptors, Chimeric AntigenXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Cancer immunotherapyHematologyLeukemiasT cellsTherapeutics

Substanzen

CD33 protein, humanReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 3Sirolimus

Autor:innen und Institutionen

  • Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Division of Hematology/Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
  • Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Seattle Children's Hospital, Seattle, Washington, USA.
  • 2seventy bio, Cambridge, Massachusetts, USA.
  • Inhibrx, Torrey Pines Science Park, La Jolla, California, USA.

Förderung

  • NCI NIH HHS
  • American Society of Hematology

Zitieren

APA

Appelbaum, J., Price, A. E., Oda, K., Zhang, J., Leung, W. H., Tampella, G., Xia, D., So, P. P., Hilton, S. K., Evandy, C., Sarkar, S., Martin, U., Krostag, A. R., Leonardi, M., Zak, D. E., Logan, R., Lewis, P., Franke-Welch, S., Ngwenyama, N., …, & Jensen, M. C. (2024). Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing. Journal of Clinical Investigation. https://doi.org/10.1172/jci162593

Vancouver

Appelbaum J, Price AE, Oda K, Zhang J, Leung WH, Tampella G, et al. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing. Journal of Clinical Investigation. 2024. doi:10.1172/jci162593

BibTeX
@article{Appelbaum2024,
  author = {Appelbaum, Jacob and Price, April E and Oda, Kaori and Zhang, Joy and Leung, Wai-Hang and Tampella, Giacomo and Xia, Dong and So, Pauline Pl and Hilton, Sarah K and Evandy, Claudya and Sarkar, Semanti and Martin, Unja and Krostag, Anne-Rachel and Leonardi, Marissa and Zak, Daniel E and Logan, Rachael and Lewis, Paula and Franke-Welch, Secil and Ngwenyama, Njabulo and Fitzgerald, Michael and Tulberg, Niklas and Rawlings-Rhea, Stephanie and Gardner, Rebecca A and Jones, Kyle and Sanabria, Angelica and Crago, William and Timmer, John and Hollands, Andrew and Eckelman, Brendan and Bilic, Sanela and Woodworth, Jim and Lamble, Adam and Gregory, Philip D and Jarjour, Jordan and Pogson, Mark and Gustafson, Joshua A and Astrakhan, Alexander and Jensen, Michael C},
  title = {Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci162593}
}
Kostenlos starten →